Navigation Links
CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising multiple dose clinical trial in healthy volunteers with its drug candidate arimoclomol. CytRx believes that the results of this trial support the use of arimoclomol in future clinical trials, including its ALS Phase IIb clinical trial, at doses up to six-fold higher than that used in its previous Phase IIa clinical trials for ALS.

CytRx plans to begin its Phase IIb clinical trial in the second half of this year, subject to U.S. Food and Drug Administration (FDA) clearance. As previously announced, this trial, planned to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites, was designed to monitor changes in the progression of disease symptoms and would be completed about 18 months after the beginning of patient enrollment. Following consultation with the FDA, CytRx is now considering various options, including increasing the size and duration of the planned trial and/or conducting a second efficacy clinical trial for ALS, possibly in parallel with the Phase IIb trial, to provide additional data to support a possible approval decision by the FDA.

CytRx expects to announce results of its recently-completed six-month open-label extension trial with arimoclomol for ALS later this week.

"It is rewarding to see significant progress toward our goal of initiating the Phase IIb clinical trial for arimoclomol this year," stated CytRx's President and CEO Steven A. Kriegsman. "Based on the results of this clinical trial we plan to proceed with a dose that is four times greater than that used in our previous Phase IIa ALS clinical trials. These study results will help us optimize
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/31/2014)... NEW YORK und KISSING, Deutschland, ... ein Hersteller und Distributor eines computerunterstützten („robotischen") ... Nachum (Homi) Shamir , ein weltweit ... seines Leitungs- und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener ...
(Date:7/31/2014)... July 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... the second quarter 2014, on Thursday, August 7, 2014 ... a live webcast and conference call at 8:00 a.m. ... management will host the call and webcast to discuss ... may be accessed by calling (800) 708-4540 (domestic) or ...
(Date:7/31/2014)... 2014 Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" ... premium branded consumer products, including commercially cultivated Cordyceps Militaris ... announced the signing of its first distributor for its ... Hubei Province located ... . The contract with the ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: ... it has completed the previously announced acquisition of BMP ... stockholders held today, BMP Sunstone stockholders approved the adoption ... Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, ...
... Conn., Feb. 24, 2011 Mira Dx announced today that ... acceptance of a pivotal breast cancer study in the January ... BRCA1 coding sequence mutations are associated with breast ... less than 5% of breast cancer risk. The research identified ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... July 31, 2014 The VitalSleep anti snoring device ... forward to help open a snorers airway to quiet snoring. ... helped her relationship with her husband by allowing them to ... years old. My snoring began about 15 years ago and I ... children could not sleep and had to head downstairs for any ...
(Date:7/31/2014)... 31, 2014 The controversy surrounding ... LLP notes that Johnson & Johnson’s Ethicon, Inc. ... remove its power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) from ... the company said it decided to do so ... devices remain uncertain.* , “In light of mounting ...
(Date:7/31/2014)... July 31, 2014 Infection prevention and ... and maintenance of products in the pharma, medical device, ... by using various products and equipment types; the two ... various materials and products. , The world market ... forecast to post a CAGR of about 7.5% through ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has shown an increased risk of spreading undetected cancers in ... market. In a letter that was to be sent ... that its laparoscopic power morcellators be returned to the company, ... of new morcellators had been suspended in April after the ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 2Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 3
... associated with enhanced communications between families and caregivers, ... for children dying from cancer, according to study ... Hospital Boston. , Published in the April 1 ... study,s findings also suggest that the parents were ...
... that Planned Parenthood affiliates in Florida,have been falsifying ... show,that what happened in California is not an ... Life League,renewed its call for a national investigation ... Florida allege falsified annual,reports., "It,s outrageous that ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... and TAMPA, Fla., March 28 ... LLC (myMatrixx) are pleased to,announce an ... bill review program and myMatrixx,s pharmacy ... first fully-integrated and automated,program between a ...
... Darwin,Professional Underwriters, Inc. (Darwin) (NYSE: DR ... Romano, who served as its senior vice ... Romano has become,associated with a competing professional ... http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ), The company ...
... March 28 Conseco, Inc. (NYSE:,CNO) announced today that ... for,the year ended December 31, 2007 with the Securities ... common stock for 2007 was $194.0,million, compared to the ... 2008 preliminary results. The reported net loss applicable to,common ...
Cached Medicine News:Health News:Study finds improvement in the care of children with cancer at the end of life 2Health News:Study finds improvement in the care of children with cancer at the end of life 3Health News:American Life League: Planned Parenthood Scandals 'Widespread' 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Conseco Files 10-K and Sets Earnings Release Date 2
HbA1c / HbCalibrator...
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
... Abnormal Control Plasmas for ... D-dimer and Free Protein ... For use with STA© ... D-DI (#0515) andSTA© LIATEST© ...
CRP Full Range (0.1-160mg/l)...
Medicine Products: